VAXIMM
Manufacturing · Switzerland · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Hochbergerstrasse 60c, Basel, Basel-City...Phone Number
+41 613169111Website
www.vaximm.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About VAXIMM
VAXIMM specializes in a new class of cytotoxic immunotherapies that leverage the gut immune system for precision treatment. Their innovative approach combines the convenience of oral administration with a targeted, systemic T-cell response. The company has a robust development pipeline aimed at addressing clinically-validated targets with novel immunotherapies. VAXIMM is committed to advancing its scientific vision and mission through its founding leadership.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is VAXIMM your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when VAXIMM launches new products
Earning: See what the market has to say on VAXIMM recently announced quarterly report
Check if VAXIMM has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at VAXIMM
Check out if VAXIMM is spiking on competitors!
Funding: Get notified immidiatlly once VAXIMM has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if VAXIMM had a recent Job posting/layoffs
VAXIMM, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined VAXIMM as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
VAXIMM is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
VAXIMM is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about VAXIMM.
VAXIMM financials insights
Gather financial insights about VAXIMM, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Unspecified
$8M
VAXIMM Tech Stack
A closer look at the technologies used by VAXIMM
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Promotion
Executive Move
Executive Moves, Promotion
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
VAXIMM News & Media
Vaximm, an OSR Company, Receives Binding Term Sheet from BCM Europe for Global Exclusive License of VXM01 with $30M Upfront and Up to $815M in Milestones
BELLVUE, Wash., Jan. 12, 2026 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today announced that its Swiss biotechnology subsidiary, Vaximm AG, has received a binding term sheet from BCM Europe AG confirming BCM Europe's interest in entering a global exclusive licensing transaction...Vaximm AG, an OSR Company, Updates Term Sheet with BCM Europe to Shorten Exclusivity Period to Three Months
BELLEVUE, Wash., Dec. 2, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH) today provided an update regarding the previously announced non-binding term sheet between its subsidiary, Vaximm AG, and BCM Europe AG ("BCME"). The parties have agreed to shorten the exclusivity period from...Vaximm and BCME link on oral cancer immunotherapy platform
Vaximm would receive $20m upfront and earn up to $815m in milestones under the deal.Vaximm AG, an OSR Company, Enters Term Sheet With BCM Europe for Potential VXM01 License with $20M Upfront and Up to $815M in Milestones
BELLEVUE, Wash., Nov. 21, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), today announced that Vaximm AG, an OSR Company, has entered into a non-binding term sheet with BCM Europe AG ("BCME"), a Swiss-based life sciences investment group and OSRH's largest shareholder, to explore...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding VAXIMM
Sign Up For FreeTo access detailed company insights
VAXIMM specializes in a new class of cytotoxic immunotherapies that leverage the gut immune system for precision treatment. Their innovative approach combines the convenience of oral administration with a targeted, systemic T-cell response. The company has a robust development pipeline aimed at addressing clinically-validated targets with novel imm... Read More
